Adults 18 to 99, any sex, with Mask Ventilation or Airway Obstruction Upper. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Expiratory Tidal Volume (Breaths 6-10)Primary· Measured immediately after placement of each oral airway; an average of 2-5 minutes.
Measured expiratory tidal volume (from video of anesthesia monitor). Each participant had measurements collected during breaths number 6-10 after the insertion of each oral airway (GOA or AOA) with the order of first treatment randomized. The average expiratory tidal volumes reported were weight standardized per kilogram of participant's body weight, meaning the expiratory measurements were divided by the participant's weight (kg). A total of 56 patients were enrolled and randomized--28 received the Guedel Oral Airway first and 28 received the Articulated Oral Airway first. The average expirat
First intervention-breaths 6 through 10
Group
Value
95% CI
Guedel Oral Airway
4.46
3.86 – 5.07
Articulated Oral Airway
3.21
2.62 – 3.79
Second intervention-breaths 6 through 10
Group
Value
95% CI
Guedel Oral Airway
3.12
2.54 – 3.70
Articulated Oral Airway
3.48
2.87 – 4.08
Inspiratory Tidal Volume (Breaths 6-10)Secondary· Measured immediately after placement of each oral airway; an average of 2-5 minutes.
Measured inspiratory tidal volume (from video of anesthesia monitor). Each participant had measurements collected during breaths number 6-10 after the insertion of each oral airway (GOA or AOA) with the order of first treatment randomized. The average inspiratory tidal volumes reported were weight-standardized per kilogram of participant's body weight, meaning the inspiratory measurements were divided by the participant's weight (kg). A total of 56 patients were enrolled and randomized--28 received the Guedel Oral Airway first and 28 received the Articulated Oral Airway first. The average insp
First intervention-breaths 6 though 10
Group
Value
95% CI
Guedel Oral Airway
6.37
5.35 – 7.40
Articulated Oral Airway
5.7
4.71 – 6.68
Second intervention-breaths 6 through 10
Group
Value
95% CI
Guedel Oral Airway
5.83
4.84 – 6.82
Articulated Oral Airway
6.72
5.70 – 7.75
Immediate Oropharyngeal Trauma From Oral Airway Randomized to be Placed FirstSecondary· Measured immediately after removal of first oral airway and before placing the second oral airway
After the first oral airway device was removed, it was visually inspected for the presence of blood and is reported as the number of subjects where blood was visualized on the initial airway device..
Group
Value
95% CI
Guedel Oral Airway Placed First
3
Articulated Oral Airway Placed First
0
Sponsor's own description
The Articulating Oral Airway (AOA) is a novel oral airway which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The investigators hypothesize that, in patients with predictors for difficult mask ventilation, the AOA will be non-inferior to the Geudel oral airway in terms of expired tidal volumes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07275502 — Prospective Development and Validation of an Objective Classification for Difficult Facemask Ventilation: the MASCAN Sco
· active not recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ron Abrons
Last refreshed: 23 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03144089.